Downing v. Abbott Laboratories

CourtDistrict Court, N.D. Illinois
DecidedSeptember 5, 2019
Docket1:15-cv-05921
StatusUnknown

This text of Downing v. Abbott Laboratories (Downing v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Downing v. Abbott Laboratories, (N.D. Ill. 2019).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION JACINTA DOWNING, ) ) Plaintiff, ) ) v. ) No. 15 C 05921 ) ABBOTT LABORATORIES and Judge John J. Tharp, Jr. ) ABBOTT MOLECULAR INC., ) ) Defendants. )

MEMORANDUM OPINION AND ORDER Plaintiff Jacinta Downing filed this suit against her employer, Abbott Molecular, Inc., alleging that it violated Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq. by discriminating against her because of her race and sex and retaliating against her for voicing her complaints about that conduct. Abbott has moved for summary judgment; for her part, Downing has moved to strike portions of declarations submitted by Abbott in support of its motion. For the reasons discussed below, Downing’s motion to strike is denied in large part and granted in part. Abbott’s motion for summary judgment, on the other hand, is granted in small part but largely denied because the record in this case is replete with material fact disputes.1

1 Abbott has also filed a motion to exclude Downing’s proffered expert testimony on “implicit bias,” which remains pending. Because the Court is denying, in large measure, Abbott’s summary judgment motion, it is not necessary to resolve Abbott’s motion to exclude Downing’s expert testimony before issuing this opinion as to summary judgment. Even without the proffered expert testimony, Downing has adduced enough evidence to support a jury verdict in her favor as to her retaliation and race discrimination claims, and Downing’s disparate impact claim, which does not survive Abbott’s motion, does not rely on the proffered expert testimony. BACKGROUND Jacinta Downing began working for Abbott Molecular, Inc., a subsidiary of Abbott Laboratories, in 2003.2 Defendants’ Statement of Facts (“DSOF”) ¶ 3, ECF No. 212. After six years as a Molecular Area Sales Manager, Downing transitioned into the role of Regional Sales Manager in 2009, which reported directly to the Division Vice President of Americas, Mark

Bridgman. As one of five regional managers, Downing supervised a team of sales representatives who were charged with selling healthcare products to hospitals, commercial laboratories, and clinics. Id. ¶¶ 2, 6. Between 2004 and 2012, Downing received “Achieved Expectations” or “Exceeded Expectations” in her overall annual performance ratings. Plaintiffs’ Corrected Statement of Facts (“PSOF”) ¶ 2, ECF No. 237. In 2011, the company began experiencing financial distress and decided to restructure its management hierarchy in response. DSOF ¶ 8. First, Bridgman terminated one of the regional managers, a white male (“M.M.”), leaving Downing (an African-American woman), C.J. (an African-American woman), M.K. (a white man), and J.G. (a white woman).3 Then, Abbott executives added a layer of management between the regional managers and Bridgman by hiring

Peter Farmakis (a white man) into a new “National Sales Director” role in October 2012. Id. ¶ 13. As National Sales Director, Farmakis directly supervised the regional managers; the managers no longer reported directly to Bridgman.

2 Except where necessary to distinguish them, Abbott Molecular and Abbott Laboratories will be referred to collectively as “Abbott.” 3 In an effort to preserve their privacy, this opinion refers to other employees whose performance and conduct is discussed herein by their initials. These individuals are not parties to this litigation and should not be burdened by publication of details of their performance evaluations. It is Abbott’s position that Farmakis immediately noticed problems with Downing’s job performance, a fact which is hotly disputed and discussed in more detail below. It is Downing’s position that Farmakis was unfairly targeting her. In July 2013, Downing complained to Employee Relations about Farmakis, alleging that he was discriminating against her because of her race. PSOF ¶ 8. According to Downing, she provided several examples of Farmakis favoring M.K., the

white male regional sales manager, and complained of an incident in which she and C.J. (the only black managers) were required to “pick up the slack” for the other two poorer performing white managers. Id. In response, Employee Relations Specialist Colleen Plettinck conducted a “climate survey” in August 2013 regarding Peter Farmakis during which she interviewed the four regional managers. DSOF ¶ 72. The results of the survey were mixed. Downing, C.J., and J.G. (the three female managers) reported that they “strongly disagreed” with the statement that Farmakis treated people in the group equally. M.K., the only male manager, reported that he felt that Farmakis did treat people equally. Pl.’s Exs. 39-42, ECF No. 213. J.G. also reported that Farmakis was “especially hard on Jay [Jacinta]” despite the fact that “her numbers [were] good.” Pl.’s Ex. 42.

Downing reported that, earlier in the month, Farmakis had made a comment along the lines of “did you hear about the dress code, no hoodies,” which Downing perceived as racist in light of the Trayvon Martin shooting incident. PSOF ¶ 9. Abbott maintains that the survey results led Sarah Longoria, Director of Business Human Relations, to believe that Farmakis needed coaching regarding his management style but that his behavior was not discriminatory.4 DSOF ¶ 72. The

4 Longoria testified in her deposition that she raised the issue of gender discrimination with Farmakis and also asked him about the “no hoodies” comment, but that she believed Farmakis when he told her that he was not discriminating based on sex (but rather managing performances that were not meeting expectations) and that he did not intend for the hoodie comment to come across as racist. Pl.’s Ex. 9 at 129:8-17, 158:1-9. results of the survey were eventually summarized and shared with Farmakis in late September 2013. In October 2013, Farmakis placed both Downing and J.G. on “coaching plans” because of their alleged performance issues. Id. ¶ 41. According to Downing, J.G. was the lowest sales performer but had not faced any disciplinary action until this time. Shortly thereafter, J.G. took

early retirement and was replaced by P.R., a white woman, at the end of 2013. Id. ¶ 12. Then, in January 2014, after Downing had earned the sales manager of the year award based on her sales performance, PSOF ¶ 17, Farmakis escalated Downing’s coaching plan to a formal 60-day Performance Improvement Plan (“PIP”) which was written and reviewed by Employee Relations Specialist Sharon Larson and Sarah Longoria. DSOF ¶¶ 44, 45. The PIP laid out various areas for improvement and expectations and explained that failure to meet those expectations would result “in a review for termination.” Defs.’ Ex. 40, ECF No. 167-30. Abbott does not contend that Farmakis had cause to initiate a termination review based on the PIP. On September 9, 2014, Downing filed a complaint with the EEOC alleging that Farmakis had discriminated against her

because of her race by subjecting her to a hostile work environment and retaliated against her by placing her on the coaching plan and PIP. Defs.’ Ex. 66, ECF No. 167-50. At some point while this was happening, Abbott management began discussing the need for a company wide reduction in force (“RIF”) to combat the ongoing sales slump. Downing maintains that discussions about a RIF began as early as October 2013; Abbott maintains they began in September 2014. DSOF ¶ 48. Regardless, Abbott executed the RIF in January 2015. Prior to doing so, Keith Chaitoff replaced Mark Bridgman as Division VP of the Americas. Id. ¶ 49. Although there is some dispute as to who had ultimate decision-making power with respect to the RIF, it is undisputed that Chaitoff and Sarah Longoria worked together to determine which U.S.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Watson v. Fort Worth Bank & Trust
487 U.S. 977 (Supreme Court, 1988)
Bonte v. U.S. Bank, N.A.
624 F.3d 461 (Seventh Circuit, 2010)
Omnicare, Inc. v. Unitedhealth Group, Inc.
629 F.3d 697 (Seventh Circuit, 2011)
Schandelmeier-Bartels v. Chicago Park District
634 F.3d 372 (Seventh Circuit, 2011)
Mucha v. Village of Oak Brook
650 F.3d 1053 (Seventh Circuit, 2011)
Moore v. Vital Products, Inc.
641 F.3d 253 (Seventh Circuit, 2011)
Diaz v. Kraft Foods Global, Inc.
653 F.3d 582 (Seventh Circuit, 2011)
Glenn E. Tagatz v. Marquette University
861 F.2d 1040 (Seventh Circuit, 1988)
Denise Coleman v. Patrick R. Donaho
667 F.3d 835 (Seventh Circuit, 2012)
Gary Millbrook v. Ibp, Inc.
280 F.3d 1169 (Seventh Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
Downing v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/downing-v-abbott-laboratories-ilnd-2019.